GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
E

Evolus EOLS · USD

Health Care · US listing · 🇺🇸 United States

Compare

6.52

-6.86%

Close of 20 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

Price performance

Chart by TradingView, with its own licensed prices

Evolus — daily EOLS Delayed
Market value
$422.6m
Last close × shares
Volume
813.6k
Shares, 20 Nov 2026

About Evolus

From its filings with the US Securities and Exchange Commission

SEC filings

Evolus is based in Newport Beach, California and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker EOLS. The SEC classifies its business as pharmaceutical preparations. In the fiscal year to 31 December 2025, it reported revenue of $297.2m and a net loss of $51.6m. At that date it held total assets of $225.9m and shareholders' equity of −$23.1m. By business, Product revenue, net brought in 99.3% of revenue, followed by Service revenue at 0.7%.

In its own words

We are a global performance beauty company delivering breakthrough products with a customer-centric approach. Our primary market is the cash-pay aesthetic market, which consists of medical products that consumers pay for directly out of pocket. Our customers are aesthetic practitioners who are properly licensed to deliver our products. By avoiding the regulatory burdens that accompany reimbursed products and pursuing an aesthetic-only non-reimbursed product strategy, we believe that we create flexibility to deliver a unique value proposition to our customers. We utilize this flexibility to drive customer adoption efforts through programs such as our consumer loyalty program, co-branded marketing programs, promotional events and pricing strategies.

Our current commercially available products and our product candidates represent two of the largest product categories within medical aesthetics, injectable neurotoxins and injectable hyaluronic acid (“HA”) gels.

Jeuveau® is a proprietary 900 kilodalton (“kDa”), purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as “frown lines,” in adults. Jeuveau® offers a 900 kDa botulinum toxin alternative to BOTOX (onabotulinumtoxinA). We believe aesthetic practitioners generally prefer the performance characteristics of the complete 900 kDa neurotoxin complex and are accustomed to injecting this formulation.

Quoted from its 10-K, filed 3 Mar 2026. Read the filing on SEC.gov ↗

More about Evolus →

How it makes its money

Revenue, year to 31 Dec 2025

  • Product revenue, net $295.0m · 99.3%
  • Service revenue $2.2m · 0.7%

Latest on Evolus

Our reporting

Next results

2 Mar 2027

Due on 2 Mar 2027. Analysts expect earnings of 0.10 a share.

Other Health Care listings

Scenario calculator

Try your own numbers. This is arithmetic, not a forecast.

Interactive

Gain or loss

—

Return

—

Leaves out fees, taxes and financing.

Frequently asked questions

What is Evolus's ticker?

Evolus trades as EOLS on its US listing, under ISIN US30052C1071.

What was Evolus's last closing price?

6.52 on 20 Nov 2026. The figure is in USD and is never converted.

When does Evolus next report results?

Results are expected on 2 Mar 2027, according to our data supplier.

Sources and methodology

Chart
TradingView
Close and company data
SEC filings and our data supplier
News
Our reporting

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.